PROCEPT BioRobotics (PRCT) Cost of Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Cost of Revenue data on file, last reported at $29.2 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 16.74% year-over-year to $29.2 million in Q1 2026; TTM through Mar 2026 was $116.0 million, a 24.89% increase from a year earlier, with the FY2025 full-year figure at $111.8 million, up 27.95% from the prior year.
• Cost of Revenue for Q1 2026 stood at $29.2 million, down from $30.1 million in the prior quarter.
• Over the last five years, Cost of Revenue for PRCT reached as high as $30.1 million in Q4 2025 and fell as low as $6.5 million in Q1 2022.
• Historically, Cost of Revenue has averaged $19.5 million across 5 years, with a median of $21.5 million in 2024.
• Across the five-year window, Cost of Revenue soared 133.03% in 2022 and increased 10.02% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $13.1 million in 2022, then jumped by 70.41% to $22.3 million in 2023, then climbed by 10.02% to $24.6 million in 2024, then increased by 22.41% to $30.1 million in 2025, then dropped by 2.94% to $29.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $29.2 million in Q1 2026, $30.1 million in Q4 2025, and $29.3 million in Q3 2025.